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evidenced by elevated C-reactive protein and low serum albumin)
has been established as an independent predictor of survival in
patients with metastatic breast cancer. However, the relationship
between these systemic inflammatory markers, clinicopathologi-
cal characteristics and cancer specific survival has not been
established in early breast cancer.
Methods: During the period June 2001–May 2008, patients with
early breast cancer presenting to two hospitals in the West of
Scotland were prospectively included into this study (n = 959).
Preoperative C-reactive protein, albumin and clinico-pathological
data were recorded for each patient. The thresholds for normal C-
reactive protein and albumin were taken as <6 mg/l and >43 g/l
respectively.
Results: The median follow-up of the survivors was 4.1 years.
During this period, 93 patients died of their cancer. On multivar-
iate analysis, tumour size (HR 2.03; 95%CI 1.41–2.91, P < 0.001),
lymph node status (HR 2.23; 95%CI 1.45–3.41, P < 0.001), hormone
receptor status (HR 1.58; 95%CI 1.24–2.00, P < 0.001) and albumin
<43 g/l (HR 1.97; 95%CI 1.28–3.01, P = 0.002) were significant inde-
pendent predictors of cancer-specific survival. Lower serum albu-
min concentrations (<43 g/l) were associated with deprivation
(P = 0.019) and significantly poorer 5-year cancer-specific survival
(85% vs. 92% P = 0.005).
Conclusions: The results of the present study show that lower
preoperative albumin concentrations, but not elevated C-reactive
protein concentrations, predict cancer-specific survival, indepen-
dent of clinico-pathologic status in early breast cancer. Albumin
may be a useful clinical prognostic factor in these patients.
doi:10.1016/j.ejcsup.2010.06.066
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We have investigated the expression pattern of the MCPH1
protein microcephalin and evaluate its prognostic importance in
breast cancer. Microcephalin is a damage response protein
involved in the regulation of BRCA1 and BRCA2 in the homolo-
gous DNA repair pathway. BRCA1 mutations are often associated
with basal-like breast cancer. MCPH1 immunohistochemistry was
performed on 319 breast cancers and correlated with pathology,
survival, ER, PR, HER2, EGFR, CK5/6, CK14 and BRCA1 data.
After performing continuous data analysis mean microcepha-
lin expression decreased with increasing grade, grades 1 and 2 vs.
grade 3 (p < 0.006). Interestingly mean microcephalin expression
was also lower in ER/PR negative (p < 0.001) and triple negative
cancers (p < 0.004). Conversely an association with HER2 positive
cancers was also identified (p < 0.03). No association was identi-
fied with basal markers or BRCA1 cytoplasmic staining.
After dichotomizing the data into low and high microcephalin
expression, reduced expression was identified in 29% (93/319) of
breast cancers. A weak association with low microcephalin
expression was identified with overall survival (OS) p = 0.1 in the
whole patient series. This was increased in ductal carcinomas
alone (HR = 0.6, 95%CI: 0.4–1, p = 0.054). Multivariate analysis of
ductal carcinomas showed that microcephalin, together with
stage, was considered an independent predictor of OS (HR = 0.5,
95%CI: 0.3–0.851, p = 0.01).
Microcephalin expression is reduced in 29% of breast cancers,
particularly in higher grade tumours and is an independent pre-
dictor of OS in ductal carcinomas. Microcephalin may prove to
be a useful biomarker for the identification of aggressive breast
cancers.
doi:10.1016/j.ejcsup.2010.06.067
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Background: Proliferation rates of tumour cells provide prog-
nostic and therapy predictive information. Mitotic index (MI), S-
phase fraction (SPF) and Ki67/MIB-1 are used to assess
proliferation.
Aim: To compare the proliferation assays and explore their
correlation.
Patients and methods: MI, SPF and 5-year follow-up data were
explored for 670 patients from the hospitals of Kalmar County.
MI, Ki67/MIB-1 and 3-year follow-up data for 403 patients from
the Sahlgrenska University Hospital were extracted.
Results: MI and Ki67 were both significantly correlated to early
recurrence, p < 0.001. The optimal correlation between MI and
Ki67 was achieved when both were separated in three groups
with cut off values for Ki67 of 10 and 30%. Spearman r = 0.69,
p < 0.0001. The 39 early distant recurrences were distributed in
the MI group 1–3, group 2–11 and group 3–25 recurrences. Two
pts with Ki67 <10% had distant recurrences, 22 with 10–30% and
15 pts in the group of Ki67 < 30%.
The combination of diploidy and low SPF identified pts with
the lowest and MI 3 those with the highest risk of distant
recurrence.
Conclusion: Mitotic index was superior to Ki67 and SPF to iden-
tify pts with inferior prognosis. The cytometric assay was supe-
rior to identify pts with the best prognosis. There was a
significant correlation between MI and Ki67 when both were
stratified into three groups.
doi:10.1016/j.ejcsup.2010.06.068
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ONCOPOOL database (n = 17,000) is of primary operable breast
cancers in women aged 670, from 12 European Breast Units,
treatment in 1990–99.
Method: LVI was regularly measured in 4 units (n = 5195) on H &
E staining. Scoring was to positive or negative. 20% were LVI+.
Results:
A. Relation to Nottingham Prognostic Index (NPI). A highly
significant rank order, 7% LVI+ lying in Excellent NPI group
to 60% in the poor groups.
B. Effect on survival – breast cancer specific (BCS)
Conclusion: LVI positivity by its effect on LN stage lowers sur-
vival within all Nottingham Prognostic Index (NPI) groups.
doi:10.1016/j.ejcsup.2010.06.069
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Introduction: As clinicians we are commonly asked by patients
‘what is my chance of surviving breast cancer?’ In recent years
numerous attempts have been made to utilise both machine
learning methods and large datasets to develop new tools to pre-
dict survival. The aim of our study was to firstly compare the per-
formance of a number of these models and secondly to introduce
a newmodel that provides a simple means of predicting the prob-
ability of survival.
Methods: The Surveillance, Epidemiology, and End Results
(SEER) data was used to build a data set of women diagnosed with
breast cancer between 1990 and 1997. We used the statistical
packages R and Weka to generate the models based on tumour
size, grade and nodal involvement. Methods applied were: sup-
port vector machines, decision trees, boosting, bagging, random
forests and Naı¨ve Bayes Decision Tree (NBTree).They were vali-
dated using 10-fold cross validation.
Results: A total of 50,895 women were included in the analysis.
Each model was generated 10 times, validated and then tested.
The best performing model was Random forests with the ability
to correctly predict the outcome in 70.56%. The NBTree model
was the second best performing model (69.26%) which also pro-
vided a probability for ten year survival.
Conclusion: Although the random forests model was the most
robust model, from a clinicians point of view, the NBTree model
produced a decision tree that can easily be integrated into patient
care and that also puts a value on the probability of survival.
doi:10.1016/j.ejcsup.2010.06.070
O-70 COMPARISON OF PREDICT AND ADJUVANT! PROGNOSTI-
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Aim: We have recently developed and validated a prognostica-
tion model (PREDICT), that predicts overall survival for women
treated for early breast cancer in the UK, based on cancer registry
data.1 We have now compared the mortality prediction from PRE-
DICT against Adjuvant! in an independent UK dataset.
Method: 10-Year overall survival (OS) and breast cancer-specific
survival (BCSS) data were available for 1065 women treated at the
Churchill Hospital in Oxford between 1986 and 1996. 10-Year pre-
dictions for OS and BCSS from PREDICT and Adjuvant! were com-
pared with the observed 10-year outcomes for these patients.
Results:Of the 1065 cases, 891 hadoptimal breast cancer surgery
that included radiotherapy following breast conserving surgery
and adequate axillary staging. The results are shown in the Table.
Actual
mortality
PREDICT Adjuvant!
All cause mortality 234 199 191
Breast cancer
specific mortality
161 151 133
Conclusion: In this UK dataset, PREDICT performed better than
Adjuvant! for both OS and BCSS. For breast cancer specific mortal-
ity, PREDICT’s estimate was within 1% of actual mortality com-
pared to a 3% difference for Adjuvant! Further comparisons in
other datasets are ongoing.
Reference:
1. Wishart GC, Azzato EM, Pharoah PDP, Greenberg DC, Rashbass
O, Kearins O, et al. PREDICT: a new UK prognostic model that
predicts survival following surgery for invasive breast cancer.
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